ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC)

CAPS Rating: 2 out of 5

Results 1 - 12 of 12

Recs

0
Member Avatar dividendum (< 20) Submitted: 3/14/2014 12:27:14 PM : Outperform Start Price: $1.26 IMUC Score: -3.80

It is going to hit 6 dollars by the end of 2014.
Biotechnology is on the rise.

Recs

2
Member Avatar zzlangerhans (99.74) Submitted: 1/21/2014 9:04:17 AM : Underperform Start Price: $1.18 IMUC Score: -2.17

ImmunoCellular is yet another dubious outfit that refuses to die after a crushing failure in a clinical trial. The share price bottomed out at 0.72 subsequent to negative results of the phase II trial of ICT-107 in GBM. No statistically significant effect was seen on overall survival, although the secondary endpoint of progression-free survival was positive. The latter doesn't really mean much - people want to live longer. Nevertheless, ImmunoCellular got in touch with their inner sliminess to run a headline that only mentioned the PFS benefit, and only described the failure to meet the primary endpoint in smaller text underneath. The failure was particularly devastating for ICT-107 optimists given the frequent touting of multiple long-term GBM survivors from a small phase I trial of ICT-107 that was conducted at a single facility by a single PI. To ICT-107 skeptics, this was further evidence of the lack of prognostic value of small open label single-arm trials where patient populations can be cherry picked to look good against historical survival data.

ImmunoCellular seems to be well on its way to doubling from the lows on the back of chest-beating from management and Seeking Alpha touts. ImmunoCellular will continue to follow the patients from the trial post-blinding and will attempt to glean some positive OS data. The company does seem bent to gathering together enough scraps from the failed phase II to put together a phase III trial. Remember that many consider initiation of a phase III to be sufficient validation of phase II, since there's no hard catalyst of drug approval or rejection involved. The flip side of that coin is that phase III trials are expensive, ICT-107 is not partnered and is unlikely to be partnered, and ImmunoCellular only has 29M in the bank. Expect a significant dilutive financing once this round of puffery levels off.

Recs

0
Member Avatar helicopterfool (25.50) Submitted: 1/17/2014 2:49:49 PM : Underperform Start Price: $1.16 IMUC Score: -3.91

per zzlang

Recs

0
Member Avatar investor17390 (< 20) Submitted: 10/21/2013 12:58:57 AM : Outperform Start Price: $2.96 IMUC Score: -66.12

according to the company, we can expect results from the ict-107 phase II trail.

Recs

0
Member Avatar K28hill (22.13) Submitted: 9/11/2013 12:48:25 PM : Outperform Start Price: $2.86 IMUC Score: -68.08

several good products progressing in the pipeline.

Recs

0
Member Avatar awosha1 (74.98) Submitted: 5/16/2013 6:36:59 AM : Outperform Start Price: $2.47 IMUC Score: -63.54

Strong pipeline. low requirement for approval. Just needs to "same or better" then current treatments for GBMF (Brain cancer). and current treatment is frankly poor. Chance of no approval is almost zero.

Recs

0
Member Avatar LouisAIrl (< 20) Submitted: 9/14/2012 8:24:02 AM : Outperform Start Price: $2.80 IMUC Score: -83.53

Research in pipeline

Recs

0
Member Avatar ayuddha (26.24) Submitted: 7/15/2012 5:20:25 PM : Outperform Start Price: $3.45 IMUC Score: -103.03

It was picked by www.hechtsoft.de Trade Alerts.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 7:42:42 PM : Outperform Start Price: $3.62 IMUC Score: -103.22

Has a cancer vaccine that appears very promising.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 6/27/2012 8:09:17 PM : Outperform Start Price: $3.37 IMUC Score: -105.49

porto. likededded it.

Recs

0
Member Avatar BuffettJunior1 (96.53) Submitted: 9/27/2011 2:06:30 PM : Underperform Start Price: $1.50 IMUC Score: +75.36

Too easy!

Recs

0
Member Avatar alomba48 (39.35) Submitted: 6/23/2011 1:13:59 PM : Outperform Start Price: $2.26 IMUC Score: -93.21

Definitely speculative, but I figure the technology is interesting and some bright phase one clinical trial results are enough for me to take the risk

Results 1 - 12 of 12

Featured Broker Partners


Advertisement